VAXX News and Press, Vaxxinity Inc. From 04/28/22

Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has co...

The Coalition for Epidemic Preparedness Innovations (CEPI) will co-fund Vaxxinity's (NASDAQ:VAXX) global Phase 3 trial of COVID-19 vaccine candidate, UB-612, as a heterologous – or mix-and-match – booster dose. CEPI would provide up to $9.25M to fund the late...

OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing...

Vaxxinity (NASDAQ:VAXX) began dosing participants in a phase 3 trial evaluating its COVID-19 booster candidate, UB-612. The company said the trial was enrolling participants 16 years and older who have completed a two-dose primary immunization regimen with an mRNA (Pfizer and B...

Pivotal Phase 3 head-to-head study will evaluate non-inferiority of heterologous booster candidate UB-612 against authorized mRNA, adenovirus vector and inactivated virus COVID-19 vaccines Agreement reached with global regulators on trial design and data package required to ...

Vaxxinity press release (NASDAQ:VAXX): Q4 GAAP EPS of -$0.48. Q4 Cash cash and equivalents $144.9M For further details see: Vaxxinity GAAP EPS of -$0.48

DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021. “2021 was a transfor...

DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinit...

Vaxxinity (VAXX +3.0%) shares are trading higher after announcing that the company’s experimental COVID-19 vaccine UB-612 generated an antibody response three times stronger than the approved mRNA vaccines following a three-dose regimen. The protein-based vaccine candidate was also fou...

Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved vaccines UB-612 elicits >3 times higher titers of neutralizing antibodies aga...